Results 31 to 40 of about 9,532 (171)
Haematologica, 2015 Pomalidomide is a distinct oral IMiD® immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects. The pivotal, multicenter, open-label, randomized phase 3 trial MM-003 compared pomalidomide + low-dose ...
Jesus F. San Miguel +22 more
doaj +1 more source
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor. [PDF]
PLoS ONE, 2017 Thalidomide-based Immunomodulatory Drugs (IMiDs®), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including ...
Brian J North +5 more
doaj +1 more source
immunomodulatory compounds lenalidomide and pomalidomide
, 2013 The IMiDs(®) immunomodulatory compounds lenalidomide and pomalidomide are agents with anti-inflammatory, immunomodulatory and anti-cancer activity. An excellent success rate has been shown for multiple myeloma in phase I/II clinical trials leading to ...
Prokar Dasgupta +11 more
core +1 more source
Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation
Advanced Science, EarlyView.Dynamic supramolecular assembly reshapes targeted protein degradation by coordinating modular degrader construction, delivery, functional integration, and intracellular assembly or activation across proteasomal, endosomal–lysosomal, and autophagy–lysosomal pathways.
Kongjun Liu +8 more
wiley +1 more source
Medicina, 2021 Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice.
Maria Livia Del Giudice +13 more
doaj +1 more source
Advanced Science, EarlyView.Here, we report a novel NIR fluorescent PROTAC platform that enables real‐time imaging and targeted degradation of Alzheimer's p‐Tau. Our lead compound effectively clears p‐Tau, reduces APP/Aβ, and alleviates cognitive deficits in AD mice. This work demonstrates a theranostic strategy for visualizing degradation and developing next‐generation AD ...
Ziwei Ren +11 more
wiley +1 more source
Pomalidomide reverses gamma-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors [PDF]
, 2016 Current therapeutic strategies for sickle cell anemia are aimed at reactivating fetal hemoglobin. Pomalidomide, a third-generation immunomodulatory drug, was proposed to induce fetal hemoglobin production by an unknown mechanism.
Papoin, J. +14 more
core +1 more source
, 2023 BackgroundDespite significant therapeutic advances over the last decade, multiple myeloma remains an incurable disease. Pomalidomide is the third Immunomodulatory drug that is commonly used to treat patients with relapsed/refractory multiple myeloma ...
Yan Zhuang (115199) +6 more
core +1 more source
Molecular Glue Degraders in Early Development for Cancer Therapy
Medicinal Research Reviews, EarlyView.ABSTRACT Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein‐protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they ...
E. Sila Ozdemir +4 more
wiley +1 more source
Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model
Frontiers in Immunology, 2018 We have previously shown that immunization with tumor antigen-loaded dendritic cells (DCs) and the immunomodulating drug, lenalidomide, synergistically potentiates the enhancing antitumor immunity in a myeloma mouse model.
Manh-Cuong Vo +12 more
doaj +1 more source